News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Stocktwits Deals and strategy
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Industry analysts have significantly upgraded their revenue forecasts for Aligos Therapeutics, Inc. (NASDAQ:ALGS) for 2026, projecting a 15% improvement in sales to US$36 million, up from a previous estimate of US$22 million. Concurrently, the expected loss per share has been reduced by 46% to …
Aligos Therapeutics announced that its partner Amoytop has dosed the first participant in a Phase 1 study of ALG-170675 in China. This investigational antisense oligonucleotide (ASO) is designed for the functional cure of chronic hepatitis B virus (HBV) infection, aiming to improve cure rates …
Aligos Therapeutics Inc. has initiated a Phase 1 study in China for ALG-170675, an antisense oligonucleotide aimed at treating chronic hepatitis B virus infection. This study, conducted in collaboration with Xiamen Amoytop Biotech Co., Ltd., will assess the drug candidate's safety, tolerability, pharmacokinetics, and …
Aligos Therapeutics announced that its partner Xiamen Amoytop Biotech has dosed the first participant in a Phase 1 study of ALG-170675 in China. This investigational antisense oligonucleotide aims for a functional cure of chronic hepatitis B virus (HBV) infection. The trial will assess safety, …
H.C. Wainwright reaffirmed a Buy rating and $50 price target for Aligos Therapeutics Inc. (NASDAQ:ALGS) following positive updates on its chronic hepatitis B virus infection treatments, including breakthrough therapy designation for pevifoscorvir sodium in China and complete enrollment of the Phase 2 B-SUPREME trial. …
Lake Street has reiterated its Buy rating on Aligos Therapeutics (ALGS.US) and maintained its target price at $45. This suggests continued confidence in the company's financial prospects and growth potential from the analyst firm.
Aligos Therapeutics, Inc. has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters, provides a brief update on the company's financial performance. Readers are encouraged to access the full report on TradingView for complete details.
Aligos Therapeutics reported its second-quarter 2026 results, showing a net loss of $(1.50)M and diluted EPS of $(0.14), which is a narrower loss compared to the previous year. The company's revenue momentum was driven by $27.8M in license revenue, primarily from an exclusive Greater …
This article reports on an SEC Form 8K filing by Aligos Therapeutics Inc. on August 6th. The filing indicates a significant event or change for the company, as reflected by its stock symbol ALGS, which showed a 16.24% increase.
Aligos Therapeutics announced its Q2 2026 financial results, reporting $27.8 million in licensing revenue and a net loss of $1.5 million. The company ended the quarter with $30.4 million in cash, excluding a $25 million upfront payment received in July 2026. Key business developments …
Aligos Therapeutics reported significant business progress and financial results for Q2 2026, highlighting advances in its liver and viral disease pipeline. Key achievements include the completion of enrollment for the Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic HBV, its Breakthrough Therapy Designation …
ALIGOS THERAPEUTICS reported a net income of USD -1.504 million for the second quarter. This financial update provides a key insight into the company's recent performance.
Aligos Therapeutics (NASDAQ: ALGS), a clinical-stage biotechnology company focusing on liver and viral diseases, announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026, before U.S. financial markets open. The company's stock rose 5.4% following this announcement, consistent with …
Aligos Therapeutics Inc (ALGS) has a current valuation score of 8.75, placing it 62nd out of 385 companies in the Biotechnology & Medical Research industry. Its P/E ratio is -0.43, indicating it is -31.58% below its recent high and significantly above its recent low. …
This article provides a technical analysis of Aligos Therapeutics Inc (ALGS), focusing on current price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 5.70, trading between a resistance of 6.23 and …
This article provides a comprehensive stock analysis of Aligos Therapeutics Inc (ALGS), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. It notes strong institutional ownership and a recent "Buy" rating from analysts with a …
This article provides an in-depth look at Aligos Therapeutics Inc's (ALGS) cash flow statements, including operating, investing, and financing activities, across quarterly and annual periods. It details various components like net income, capital expenditures, and changes in working capital. The piece also includes an …
This article from TradingKey provides a revenue breakdown for Aligos Therapeutics Inc (ALGS). However, it states that relevant data regarding business segments, regional revenue, and profit contribution for ALGS have not yet been disclosed by the company. The page also displays current stock information …
Aligos Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for liver diseases and viral infections, including chronic hepatitis B (HBV), MASH, and coronaviruses. The company's pipeline features lead candidates like ALG-000184 for HBV, ALG-055009 for MASH, and ALG-097558 for coronavirus infections. …
This article provides details on Aligos Therapeutics Inc (ALGS) stock, specifically focusing on its dividend history and stock split events. It states that no dividends have been distributed in the past five years and lists multiple upcoming stock split events scheduled for August 15, …
This article details the shareholder structure of Aligos Therapeutics Inc (ALGS), listing its major shareholders and their proportions, as well as a breakdown of shareholder types. It also provides institutional shareholding data over several quarters and recent shareholder activity with changes in holdings.
The article discusses real-time trading signals for Aligos Therapeutics Inc. (ALGS), highlighting weak sentiment across all time horizons that supports a short bias. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also …
Aligos Therapeutics, Inc. (ALGS) is scheduled to release its Q2'26 earnings on July 30, with an estimated revenue of $24.68 million and an anticipated EPS of ($1.09). The article provides a table detailing past revenue and EPS performance, including reported and estimated figures and …
H.C. Wainwright has reiterated its Buy rating for Aligos Therapeutics (ALGS.US) and maintained a target price of $50. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance and potential.
Search by ticker symbol or company name and select a result to open its chart.